TBP.V - Tetra Bio-Pharma Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.1950
-0.0050 (-2.50%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.2000
Open0.1950
Bid0.1900 x 0
Ask0.2100 x 0
Day's Range0.1900 - 0.2050
52 Week Range0.1700 - 1.1900
Volume314,711
Avg. Volume278,044
Market Cap41.504M
Beta (3Y Monthly)-0.34
PE Ratio (TTM)N/A
EPS (TTM)-0.0880
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.75
  • GlobeNewswire

    Tetra Bio-Pharma Secures Financing for Hemp Energy Drink Business

    Tetra Bio-Pharma Inc., (TBP.V) (TBPMF), a leader in drug discovery and development for cannabinoid-based therapeutics, today announced its subsidiary, 2714140 Ontario Inc., has secured financing of CAD $3,000,000 in the form of convertible notes, to purchase the full rights to the Hemp Energy Drink (HED) formulation. The notes are convertible into shares of 2714140 Ontario Inc., which remains a fully owned subsidiary of Tetra. The convertible notes allow 2714140 Ontario Inc. to manufacture and distribute HED worldwide and fund ongoing operations for the business.

  • GlobeNewswire

    Tetra Bio-Pharma Joins BIOTECanada

    Tetra Bio-Pharma Inc. (“Tetra” or “TBP”) is pleased to announce that the Corporation has become a member of BIOTECanada, a national industry association with over 200 members that represents Canada’s health, industrial and agricultural biotechnology sectors. BIOTECanada’s mission is to lead the advancement of a globally competitive Canadian biotechnology ecosystem through constructive working relationships with policymakers and regulators. The organization also seeks to increase investment in Canadian biotechnology innovation, research and commercialization with the aim of establishing globally competitive and commercial Canadian-based biotechnology companies.

  • GlobeNewswire

    Tetra Bio-Pharma Confirms Regulatory Strategy of Lead Product CAUMZ™ and Strengthens Management Team

    Tetra Bio-Pharma Inc., (TSX-V) (TBPMF), a leader in drug discovery and development for cannabinoid-based therapeutics, today confirmed its regulatory strategy of its CAUMZTM (PPP011) inhalation drug product and provided additional updates on its progress with U.S. Food and Drug Administration (FDA) for an expedited review. Additionally, the company provided updates on its plans and preparations for commercial launch of CAUMZTM, which include the appointments of key strategic personnel. “Tetra’s regulatory team has made tremendous progress and we are pleased to confirm our regulatory strategy of CAUMZTM.

  • GlobeNewswire

    Tetra Bio-Pharma Provides Management Update on Tetra Natural Health’s Commercial Activities

    Tetra Natural Health (“TNH”) a wholly owned subsidiary of Tetra Bio-Pharma Inc., (“Tetra” or the “Company”) (TSX VENTURE:TBP) (TBPMF) is pleased to provide an update on its initiatives to bring its Awaye™ topical product for pain relief to the market globally and its activities to commercialize additional natural health products and non-prescription drugs in Canada and the USA. TNH is focused on entering into distribution partnerships for the commercialization of its OTC (Over-The-Counter) pain medications in the US$ 19 billion dollar market, which is expected to see steady growth according, to Future Market Insights.

  • GlobeNewswire

    Tetra Bio-Pharma Provides Management Update on Commercializing its Inhalation Drug Caumz®

    The previous financing has allowed Tetra to successfully lay the foundation for execution of the treatment phase of its ongoing Phase 3 clinical trial and to advance the ophthalmic program (PPP003). The Serenity© trial is designed to provide regulators with data from a single well-designed pivotal clinical trial for an intended use involving a serious medical condition. This data will be substantiated by Tetra’s existing body of clinical and scientific data.

  • GlobeNewswire

    Tetra Bio-Pharma Provides Regulatory Update for Its CAUMZ(TM) Kit 

    Tetra Bio-Pharma Inc., (TBP.V) (TBPMF), a leader in drug discovery and development for cannabinoid-based therapeutics, today announced the U.S. Food and Drug Administration (FDA) has determined that the company’s CAUMZ Kit can be evaluated as a combination drug/device product. The CAUMZ Kit is comprised of two constituents:  Tetra’s lead drug CAUMZ and the Mighty Medic device of Storz & Bickel, a wholly owned subsidiary of Canopy Growth.

  • GlobeNewswire

    Tetra Bio-Pharma Announces Joint Venture with Thorne and Onegevity Health to Form CB2 Therapeutics

    Tetra Bio-Pharma Inc., (TBP.V) (TBPMF), a leader in drug discovery and development for cannabinoid-based therapeutics, today announced it has signed an agreement with Thorne Research Inc. and Onegevity Health LLC to form a joint venture, CB2 Therapeutics Inc., a company focused on leveraging the power of the endocannabinoid system (ECS) using innovative multi-omics and multi-targeted therapeutic options to become a leader in the management of chronic inflammatory conditions. CB2 Therapeutics will focus on developing compounds for chronic inflammatory conditions with high unmet needs or that are poorly served with existing therapies.

  • GlobeNewswire

    Tetra Bio-Pharma Engages LifeSci Advisors and LifeSci Public Relations as Strategic Partners

    Tetra Bio-Pharma Inc., a leader in drug discovery and development for cannabinoid-based therapeutics, announced today the company has engaged LifeSci Advisors LLC, a leading investor relations consultancy serving life science companies, and LifeSci Public Relations LLC, a corporate communications firm helping clients engage their corporate audiences and achieve their business objectives via a broad array of traditional, social and digital media tools. LifeSci will work to implement and execute a comprehensive investor relations and communications program that will include analyst and investor targeting/outreach, non-deal roadshows, corporate communications, media engagement, social media and Key Opinion Leader (KOL) events.

  • CNW Group

    Tetra's Officers and Employees Participate in Private Placement

    ORLEANS, ON , Aug. 2, 2019 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") is pleased to announce that it has completed the non-brokered private placement offering (the "Private Placement") announced on July 30 , in which some of the Corporation's directors, officers, consultants and employees, as well as certain of their associates, purchased an aggregate of 870,000 units ("Units") of the Corporation at a price of $0.30 per Unit for aggregate gross proceeds of $261,000 . Each Unit issued in the Private Placement consists of one common share of the Corporation (a "Common Share") and one Common Share purchase warrant (a "Warrant"), with each Warrant entitling the holder thereof to purchase one Common Share at an exercise price of $0.40 per Common Share for a period of 36 months following the closing of the Private Placement.

  • GlobeNewswire

    The New Hemp Energy Drink Will Be Offered to Consumers in 700 Additional Stores in Five Provinces

    Tetra Natural Heath, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (TBPMF), is pleased to announce that one of the largest food and convenience store chains in North America has committed to carry the Hemp Energy Drink in over 600 stores, bringing the total number of new stores offering the product in the past two weeks to approximately 700 stores located in five provinces of Canada including: British-Columbia, Alberta, Saskatchewan, Manitoba and Ontario. The distribution commitment is for the three popular flavours of the Hemp Energy Drink – Classic, Mango and Raspberry. "We are very pleased with this agreement because the demand for our Hemp Energy Drink has been extremely positive since the product launch," said Tetra Natural Health CEO Richard Giguère.

  • GlobeNewswire

    Tetra Bio-Pharma’s Management Post Financing Corporate Update

    Tetra is a bio-pharma company with a drug pipeline covering ophthalmic conditions, chronic pain and oncology. Over the past year the corporation has secured granted patents to render its drug portfolio attractive to Pharmaceutical companies.

  • GlobeNewswire

    The New Hemp Energy Drink Will Soon Be Available In More Than 500 Stores in Quebec

    Tetra Natural Health Inc., a division of Tetra Bio-Pharma Inc. (TSX VENTURE: TBP) (TBPMF), today announced that it has signed an agreement with Distribution AB inc. for the distribution of the three flavours of the new Hemp Energy Drink in more than 500 grocery and convenience stores located on the south shore of the St. Lawrence River, mainly in the Montéregie, Eastern Townships, Centre du Québec and Mauricie region on the north shore. The Hemp Energy Drink should be available to consumers in several stores in these regions before the end of July. "Consumers appreciate the qualities of the Hemp Energy Drink (HED) and its energy inducing properties.

  • CNW Group

    Tetra Bio-Pharma Announces Closing of Unit Offering

    ORLEANS, ON , July 12, 2019 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") a clinical-stage biopharmaceutical corporation with its primary focus in cannabinoid‑based drug discovery and development (TBP.V) (TBPMF), is pleased to announce it has closed its previously announced short form prospectus offering of units of the Corporation, including the exercise in full of the Agents' (as defined below) over-allotment option. A total of 26,833,332 units (the "Units") of the Corporation were sold at a price of $0.30 per Unit, for aggregate gross proceeds of approximately $8,050,000 (the "Offering").

  • GlobeNewswire

    Panag Pharma Receives a Repayable $500,000 Contribution from the Atlantic Canada Opportunities Agency (ACOA)

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V) (TBPMF), is pleased to announce that its wholly owned subsidiary Panag Pharma Inc. has received a repayable Government of Canada contribution of $500,000 through the Atlantic Canada Opportunities Agency’s (ACOA) Business Development Program. The Program creates opportunities for economic growth in Atlantic Canada by helping businesses become more competitive, innovative and productive. “We are extremely pleased to have ACOA’s support,” said Chris MacLean, Chief Operating Officer of Panag Pharma Inc. “This contribution clearly underlines the confidence the Agency has in our strategic direction to further grow our business and to our commitment to the Province of Nova Scotia and Atlantic Canada.

  • GlobeNewswire

    Tetra Bio-Pharma Comments on Recent Trading Activity at the Request of IIROC

    Tetra Bio-Pharma (TBP.V) (TBPMF) is a biopharmaceutical multifaceted corporation with its primary focus in cannabinoid-based drug discovery and development with a clinical trial program aimed at bringing novel drugs and treatments to patients and their healthcare providers. Tetra Bio-Pharma’s subsidiary, Tetra Natural Health, also focuses on the development and commercialization of natural health and self-care products as well as the sale of its hemp energy drinks.

  • Spyder Cannabis Celebrates Canada Day Weekend with Launch of New Hemp Energy Drink Line
    Newsfile

    Spyder Cannabis Celebrates Canada Day Weekend with Launch of New Hemp Energy Drink Line

    Vaughan, Ontario--(Newsfile Corp. - June 26, 2019) - Spyder Cannabis Inc. (TSXV: SPDR) ("Spyder Cannabis" or the "Company") is excited to announce that, in celebration of Canada Day, it will launch its new Hemp Energy Drink line over the Canada Day long weekend, on June 29, across its existing Ontario locations, as well as its two brand new accessories stores in Niagara Falls and Pickering, set to open this weekend. Samples will be ...

  • CNW Group

    Tetra Bio-Pharma Inc. Announces Pricing of Unit Offering

    OTTAWA , June 24, 2019 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation"), a biopharmaceutical multifaceted corporation with its primary focus in cannabinoid‑based drug discovery and development (TBP.V) (TBPMF), is pleased to announce the price of its marketed public offering of units of the Corporation (each a "Unit") previously announced on June 19, 2019 (the "Offering"). The Offering will be conducted at a price of $0.30 per Unit. Each Unit will consist of one common share in the capital of the Corporation (each a "Common Share") and one Common Share purchase warrant of the Corporation (each a "Warrant").

  • CNW Group

    Tetra Bio-Pharma Inc. Announces Voting Results of 2019 Annual General and Special Meeting

    ORLEANS, ON , June 21, 2019 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP) (TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that all matters presented for approval at the Corporation's annual general and special meeting (the "Meeting") of shareholders of the Corporation held in Montréal, province of Québec, on June 20, 2019 , were approved. All of the nominees listed in Tetra's management information circular dated May 22, 2019 (the "Circular") were elected as directors of the Corporation until the next annual meeting of shareholders or until their successors are elected or appointed, to the exception of Mr. Benoit Chotard , whose nomination for election as director of the Corporation was withdrawn by the Corporation after he announced his resignation, effective as of June 14, 2019 , as indicated in the press release issued on June 14, 2019 .

  • CNW Group

    Tetra Bio-Pharma Inc. Announces Proposed Offering of Units

    OTTAWA , June 19, 2019 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company"), a biopharmaceutical multifaceted corporation with its primary focus in cannabinoid‑based drug discovery and development (TBP.V) (TBPMF), is pleased to announce that it has filed and received a receipt for a preliminary short form prospectus (the "Preliminary Prospectus") in connection with a proposed offering of units ("Units") for minimum gross proceeds of C$3,500,000 and maximum gross proceeds of C$7,000,000 (the "Offering"). Echelon Wealth Partners Inc. (the "Lead Agent") and Paradigm Capital Inc. (collectively with the Lead Agent, the "Agents") will conduct the Offering on a commercially reasonable best efforts basis as the Company's agents for the Offering in each of the provinces of Canada , except Québec.

  • GlobeNewswire

    New Hemp Energy Drink to be offered to consumers in cannabis accessory stores, vapes stores, and kiosks in Canada and the US

    Tetra Natural Health, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (TBPMF), today announced that it has signed an exclusive agreement with Spyder Cannabis Inc. (TSX VENTURE: SPDR) (“Spyder”) to distribute the three flavors of its Hemp Energy Drink in cannabis accessory stores and vapes stores in Canada and the US. “We are very excited to be adding the Hemp Energy Drink to our portfolio of premium brands that will be available to our growing clientele,” stated Daniel Pelchovitz, CEO and President of Spyder. “This exclusive agreement allows us to take another step in implementing our distribution strategy and achieving our goal of making our Hemp Energy Drink accessible to all consumers “ said Richard Giguère, CEO of Tetra Natural Health “Consumers appreciate the qualities of the Hemp Energy Drink (HED) including the fact that it contains more natural ingredients than other energy drinks, and is the first energy drink made with hemp available in the country” adds Derek Theriault, National Sales Director of Tetra Natural Health.

  • GlobeNewswire

    Tetra Bio-Pharma’s Management Provides Corporate Update Ahead of Annual General Meeting

    Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TBP.V) (TBPMF), a bio-pharmaceutical company engaged in cannabinoid-derived drug discovery and development, is pleased to provide investors with an update on our research, regulatory and commercial activities.

  • CNW Group

    Tetra Bio-Pharma Inc. Announces Change of Annual General Meeting Time

    ORLEANS, ON , June 17, 2019 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TBP.V) (TBPMF), a global leader in cannabinoid-based drug development and discovery, wishes to announce a change in the previously set time for the Corporation's Meeting, which was originally scheduled for Thursday, June 20, 2019 at 2:00 p.m. (Eastern Daylight Time) . Due to last minute impracticability reasons, the Meeting will now be held at 10:00 a.m. (Eastern Daylight Time) . Tetra Bio-Pharma (TBP.V) (TBPMF) is a biopharmaceutical multifaced corporation with its primary focus in cannabinoid-based drug discovery and development with a clinical trial program aimed at bringing novel drugs and treatments to patients and their healthcare providers.

  • GlobeNewswire

    Tetra Bio-Pharma Announces PPP003 Program Update Following Type B Meeting With U.S. FDA

    Tetra Bio-Pharma Inc., (“Tetra” or the “Company”) a leader in cannabinoid-derived drug discovery and development (TSX VENTURE:TBP) (TBPMF) today announced that it conducted a Type B meeting with the United States Food and Drug Administration (FDA) for its non-controlled cannabinoid drug product PPP003 slated for the treatment of painful dry eye. The FDA confirmed the proposed quality information requirements for initiating the Phase II trial in patients.  This included a container closure system, stability plans, drug substance and drug product specifications.  The FDA also provided feedback on the GLP toxicology requirements to initiate the Phase II trial.

  • CNW Group

    Tetra Bio-Pharma Inc. Announces Director Resignation

    ORLEANS, ON , June 14, 2019 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TBP.V) (TBPMF), a global leader in cannabinoid-based drug development and discovery, wishes to announce that Mr. Benoit Chotard has tendered his resignation as director of the Corporation, effective immediately, in order to devote time to manage his other professional commitments. Furthermore, Mr. Chotard has advised the Corporation that he will not stand for re-election to the board of directors of the Corporation. The Corporation hereby wishes to withdraw his nomination for election as a director at the upcoming annual general meeting of shareholders scheduled to be held on June 20, 2019 (the "Meeting").